Immune‐related dermatitis during combined treatment with pembrolizumab and axitinib in a patient with metastatic renal cell\x92carcinoma with stasis dermatitis

INTRODUCTION: The combination of pembrolizumab and axitinib has recently been approved as a first‐line treatment for previously untreated metastatic renal cell carcinoma. However, immune‐related adverse events are not well known. CASE PRESENTATION: A 65‐year‐old male was diagnosed with renal cell ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Imai, Shunsuke, Nakamura, Masaki, Chujo, Satomi, Ooki, Ryousuke, Inoue, Yasushi, Horiuchi, Hajime, Morikawa, Teppei, Uchino, Keita, Igarashi, Atsuyuki, Shiga, Yoshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560444/
https://www.ncbi.nlm.nih.gov/pubmed/34755064
http://dx.doi.org/10.1002/iju5.12356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560444/
https://www.ncbi.nlm.nih.gov/pubmed/34755064
http://dx.doi.org/10.1002/iju5.12356

Ejemplares similares